DEA Advances Psilocybin Rescheduling Petition to HHS for Scientific Review

The U.S. Drug Enforcement Administration has taken a crucial step toward potential psilocybin rescheduling by forwarding a petition to the Department of Health and Human Services for scientific review. This regulatory milestone represents significant progress in the decades-long effort to integrate psychedelics into mainstream medicine, with Psylutions, Colorado's first licensed regulated cultivator and manufacturer of psilocybin, applauding the development.

Rhonda DeSantis, founder of Psylutions, stated that this decision reflects a long-overdue alignment between policy and science, bringing healing one step closer to those who need it most. The company has positioned itself to help build a future where psilocybin therapy is safe, regulated, and accessible through licensed cultivation, precision dosing, and an established partnership network already operating in Colorado.

If psilocybin is moved from Schedule I to Schedule II of the Controlled Substances Act, patients in palliative care and veterans suffering from PTSD would be among the first to benefit through expanded pathways like Right to Try. Rescheduling would also accelerate research opportunities and expand access for clinicians and licensed healing centers, potentially transforming mental health treatment approaches.

Henry Baskerville, General Counsel and Partner at Psylutions, described this development as signaling a regulatory awakening, noting that agencies are beginning to engage with medical evidence over stigma. He emphasized that psychedelics hold even greater potential for significant medical applications than cannabis, requiring the highest standards during this transition period.

Psylutions has invested heavily in infrastructure to meet safety and precision standards, including strain optimization, lab-verified dosing, and triple HEPA filtration systems to mitigate contamination risk. The company already partners with over 50% of healing centers operating across Colorado to provide regulated psilocybin solutions for chronic pain, trauma relief, end-of-life care, and broader mental wellness. More information about their operations is available at https://ThePsylutions.com.

DeSantis added that once psilocybin is rescheduled from Schedule I, patients facing terminal illness and veterans at risk of suicide will finally have safe, legal access through Right to Try provisions. The company remains committed to ensuring that access is built on medicine that is effective, rigorously verified, and responsibly produced, setting new standards for safety, purity, and purpose in the regulated psychedelics industry.